TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT.


Journal

EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380

Informations de publication

Date de publication:
10 10 2022
Historique:
revised: 13 07 2022
received: 09 02 2022
accepted: 14 07 2022
pubmed: 4 8 2022
medline: 12 10 2022
entrez: 3 8 2022
Statut: ppublish

Résumé

In some types of cancer, telomere length is maintained by the alternative lengthening of telomeres (ALT) mechanism. In many ALT cancers, the α-thalassemia/mental retardation syndrome X-linked (ATRX) gene is mutated leading to the conclusion that the ATRX complex represses ALT. Here, we report that most high-grade pediatric osteosarcomas maintain their telomeres by ALT, and that the majority of these ALT tumors are ATRX wild-type (wt) and instead carry an amplified 17p11.2 chromosomal region containing TOP3A. We found that TOP3A was overexpressed in the ALT-positive ATRX-wt tumors consistent with its amplification. We demonstrated the functional significance of these results by showing that TOP3A overexpression in ALT cancer cells countered ATRX-mediated ALT inhibition and that TOP3A knockdown disrupted the ALT phenotype in ATRX-wt cells. Moreover, we report that TOP3A is required for proper BLM localization and promotes ALT DNA synthesis in ALT cell lines. Collectively, our results identify TOP3A as a major ALT player and potential therapeutic target.

Identifiants

pubmed: 35920001
doi: 10.15252/emmm.202215859
pmc: PMC9549729
doi:

Substances chimiques

Nuclear Proteins 0
DNA 9007-49-2
DNA Helicases EC 3.6.4.-
ATRX protein, human EC 3.6.4.12
X-linked Nuclear Protein EC 3.6.4.12
TOP3A protein, human EC 5.6.2.2
DNA Topoisomerases, Type I EC 5.99.1.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e15859

Informations de copyright

© 2022 The Authors. Published under the terms of the CC BY 4.0 license.

Références

J Biol Chem. 2013 Mar 1;288(9):6342-50
pubmed: 23329831
Sci Rep. 2019 Dec 13;9(1):19110
pubmed: 31836759
Genes Dev. 2019 Feb 1;33(3-4):221-235
pubmed: 30692206
Oncogene. 2009 Oct 29;28(43):3765-74
pubmed: 19684619
Mol Cell Biol. 2004 Nov;24(22):9948-57
pubmed: 15509797
Exp Mol Med. 2017 Apr 28;49(4):e324
pubmed: 28450737
Cytogenet Genome Res. 2016;150(1):52-59
pubmed: 27846620
Nat Struct Mol Biol. 2007 Jul;14(7):581-90
pubmed: 17589526
Mol Cell Biol. 1995 Sep;15(9):4745-53
pubmed: 7651392
Mol Cell. 2019 Oct 3;76(1):27-43.e11
pubmed: 31447390
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Childs Nerv Syst. 2021 Mar;37(3):809-818
pubmed: 33128602
Cancer Genet. 2021 Nov;258-259:85-92
pubmed: 34666222
EMBO J. 2008 May 21;27(10):1513-24
pubmed: 18418389
Mol Cell Biol. 2005 Apr;25(7):2708-21
pubmed: 15767676
PLoS One. 2018 Sep 18;13(9):e0204159
pubmed: 30226859
Cancer Genet Cytogenet. 2002 Dec;139(2):91-6
pubmed: 12550767
Nature. 2019 Mar;567(7749):473-478
pubmed: 30894748
Cancer Res. 2007 Dec 15;67(24):11565-75
pubmed: 18089785
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5
pubmed: 20837533
Nat Struct Mol Biol. 2020 Dec;27(12):1152-1164
pubmed: 33046907
Mol Cell. 2019 Oct 3;76(1):11-26.e7
pubmed: 31400850
Cancer Res. 2007 Feb 15;67(4):1513-9
pubmed: 17308089
Mod Pathol. 2015 Dec;28(12):1545-54
pubmed: 26428317
Science. 2017 Sep 29;357(6358):1416-1420
pubmed: 28818973
Nat Commun. 2020 Feb 5;11(1):733
pubmed: 32024817
Front Oncol. 2020 Jan 21;9:1518
pubmed: 32039009
Cell Rep. 2014 Apr 10;7(1):104-12
pubmed: 24703847
Nat Commun. 2015 Dec 03;6:8940
pubmed: 26632267
PLoS Genet. 2012;8(7):e1002772
pubmed: 22829774
Trends Cancer. 2020 Mar;6(3):247-260
pubmed: 32101727
Cell Rep. 2019 Jan 22;26(4):955-968.e3
pubmed: 30673617
Mol Cell. 2007 Jul 6;27(1):163-9
pubmed: 17612498
Genes Chromosomes Cancer. 2004 Jan;39(1):11-21
pubmed: 14603437
Nat Struct Mol Biol. 2014 Feb;21(2):167-74
pubmed: 24413054
Nat Rev Cancer. 2020 Oct;20(10):608-623
pubmed: 32782366
Nat Commun. 2019 May 28;10(1):2252
pubmed: 31138797
Mol Biol Cell. 2020 Aug 15;31(18):2048-2056
pubmed: 32579423
Cancer Genet Cytogenet. 2004 Jul 1;152(1):8-14
pubmed: 15193436
Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
Clin Cancer Res. 2005 Jan 1;11(1):217-25
pubmed: 15671549
Cancer Res. 1999 Sep 1;59(17):4175-9
pubmed: 10485449
Elife. 2018 Mar 27;7:
pubmed: 29580382
Nat Rev Cancer. 2015 Jun;15(6):334-46
pubmed: 25998713
Oncotarget. 2016 May 10;7(19):27208-19
pubmed: 27028851
J Biol Chem. 2006 May 12;281(19):13717-13723
pubmed: 16546998
J Biol Chem. 2007 Oct 5;282(40):29314-22
pubmed: 17693401
Cell Death Dis. 2016 May 12;7:e2220
pubmed: 27171262
Hum Mol Genet. 1997 Jun;6(6):921-6
pubmed: 9175740
Cell. 2009 Jul 10;138(1):90-103
pubmed: 19596237
Nat Rev Genet. 2010 May;11(5):319-30
pubmed: 20351727
Nat Biotechnol. 2009 Dec;27(12):1181-5
pubmed: 19935656
Trends Biochem Sci. 2013 Sep;38(9):461-6
pubmed: 23916100
Nat Commun. 2021 Mar 10;12(1):1552
pubmed: 33692341
Oncogene. 2003 Aug 14;22(34):5358-61
pubmed: 12917637
Cell Rep. 2016 Nov 8;17(7):1858-1871
pubmed: 27829156
PLoS Genet. 2015 Oct 22;11(10):e1005570
pubmed: 26492073
Genes Dev. 2019 Jul 1;33(13-14):814-827
pubmed: 31171703
Genome Res. 2010 Mar;20(3):351-60
pubmed: 20110566
EMBO Mol Med. 2022 Oct 10;14(10):e15859
pubmed: 35920001
Nature. 2016 Nov 3;539(7627):54-58
pubmed: 27760120
Oncogene. 1994 Mar;9(3):719-25
pubmed: 8108114
Nat Genet. 2017 Mar;49(3):349-357
pubmed: 28135248
Nat Commun. 2021 May 10;12(1):2584
pubmed: 33972520
Brain Pathol. 2013 May;23(3):237-43
pubmed: 22928601
PLoS One. 2011 Feb 15;6(2):e17036
pubmed: 21347226
Cancer Res. 2004 Apr 1;64(7):2324-7
pubmed: 15059879
Clin Cancer Res. 2019 Nov 1;25(21):6346-6356
pubmed: 31175097
Ann Oncol. 2016 Apr;27(4):738-44
pubmed: 26787232
Science. 2011 Jul 22;333(6041):425
pubmed: 21719641
Cancer Res. 1995 Mar 15;55(6):1334-8
pubmed: 7882332
Nature. 2003 Dec 18;426(6968):870-4
pubmed: 14685245
Science. 2015 Jan 16;347(6219):273-7
pubmed: 25593184
Blood Cancer J. 2015 Mar 13;5:e292
pubmed: 25768406
Nat Commun. 2017 Nov 7;8(1):1356
pubmed: 29116081
Cell Biosci. 2020 Mar 10;10:30
pubmed: 32175073
J Clin Oncol. 2004 Sep 15;22(18):3790-7
pubmed: 15365076
EMBO J. 2017 Oct 2;36(19):2907-2919
pubmed: 28877996
Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12430-5
pubmed: 19581589
Mol Cell. 2021 Mar 4;81(5):1027-1042.e4
pubmed: 33453166
Eur J Cancer. 2007 Mar;43(4):752-61
pubmed: 17267204
Cancer Lett. 2019 Aug 28;458:56-65
pubmed: 31128216
Curr Opin Genet Dev. 2020 Feb;60:1-8
pubmed: 32114293
Cancer Res. 2003 Apr 15;63(8):1759-63
pubmed: 12702558
Curr Opin Genet Dev. 2020 Feb;60:25-30
pubmed: 32119936
Genes Chromosomes Cancer. 2003 Jan;36(1):7-16
pubmed: 12461745
Trends Cell Biol. 2022 Jan;32(1):45-57
pubmed: 34384659
Adv Exp Med Biol. 2020;1258:141-155
pubmed: 32767239
Mol Cell Biol. 2017 Sep 26;37(20):
pubmed: 28760773
Nature. 2015 Oct 29;526(7575):700-4
pubmed: 26466568
Brain Tumor Pathol. 2020 Apr;37(2):33-40
pubmed: 32227259
Cancer Discov. 2019 Jan;9(1):46-63
pubmed: 30266815
FEBS Lett. 2010 Sep 10;584(17):3800-11
pubmed: 20542034
Cell. 2010 Mar 5;140(5):678-91
pubmed: 20211137
Open Biol. 2018 Apr;8(4):
pubmed: 29695617
Mol Cancer Res. 2019 Dec;17(12):2480-2491
pubmed: 31611308
Curr Opin Genet Dev. 2021 Apr;67:61-66
pubmed: 33285512
Genes Chromosomes Cancer. 2003 Nov;38(3):215-25
pubmed: 14506695
Nat Struct Mol Biol. 2018 Sep;25(9):868-876
pubmed: 30177760
Nature. 2007 Mar 15;446(7133):338-41
pubmed: 17293877
Genes Dev. 2020 May 1;34(9-10):650-662
pubmed: 32217664
Genes Chromosomes Cancer. 1995 Sep;14(1):15-21
pubmed: 8527379

Auteurs

Alexandre de Nonneville (A)

Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Team « Telomere and Chromatin ». Equipe labellisée Ligue Nationale Contre Le Cancer, Aix-Marseille Univ, Marseille, France.
Cancer Research Unit, Faculty of Medicine and Health, Children's Medical Research Institute, University of Sydney, Westmead, NSW, Australia.
Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.
Department of Medical Oncology, CRCM, CNRS, INSERM, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.

Sébastien Salas (S)

Department of Medical Oncology, Assistance Publique Hôpitaux de Marseille - Timone Hospital, Marseille, France.

François Bertucci (F)

Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.
Department of Medical Oncology, CRCM, CNRS, INSERM, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.

Alexander P Sobinoff (AP)

Telomere Length Regulation Unit, Faculty of Medicine and Health, Children's Medical Research Institute, University of Sydney, Westmead, NSW, Australia.

José Adélaïde (J)

Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.

Arnaud Guille (A)

Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.

Pascal Finetti (P)

Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.

Jane R Noble (JR)

Cancer Research Unit, Faculty of Medicine and Health, Children's Medical Research Institute, University of Sydney, Westmead, NSW, Australia.

Dimitri Churikov (D)

Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Team « Telomere and Chromatin ». Equipe labellisée Ligue Nationale Contre Le Cancer, Aix-Marseille Univ, Marseille, France.

Max Chaffanet (M)

Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.

Elise Lavit (E)

Department of Medical Oncology, Assistance Publique Hôpitaux de Marseille - Timone Hospital, Marseille, France.

Hilda A Pickett (HA)

Telomere Length Regulation Unit, Faculty of Medicine and Health, Children's Medical Research Institute, University of Sydney, Westmead, NSW, Australia.

Corinne Bouvier (C)

Department of Pathology, Assistance Publique Hôpitaux de Marseille - Timone Hospital, Marseille, France.

Daniel Birnbaum (D)

Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.

Roger R Reddel (RR)

Cancer Research Unit, Faculty of Medicine and Health, Children's Medical Research Institute, University of Sydney, Westmead, NSW, Australia.

Vincent Géli (V)

Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Team « Telomere and Chromatin ». Equipe labellisée Ligue Nationale Contre Le Cancer, Aix-Marseille Univ, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH